The Fred Hollows Foundation and the Australian Council for International Development (ACFID) are taking the lead in a campaign calling on the Australian Government to invest in healthcare in the Indo-Pacific. Read more
Mark Zuckerberg teases new EssilorLuxottica smart glasses with neural interface
Facebook founder Mr Mark Zuckerberg has travelled to Milan to meet with EssilorLuxottica chairman Mr Leonardo Del Vecchio where he hinted at a new smart glasses project featuring a neural interface wristband. Read more
EyeQ-NOC acquires The Spectacle Site optometry group
The Spectacle Site has been acquired by EyeQ Optometrists-National Optical Care (NOC), with the deal comprising five Melbourne and Victorian practices and a Canberra location trading as Specialeyes. Read more
Fresh six-year MiYOSMART data unveiled at ARVO
New six-year data on Hoya Vision Care’s defocus myopia spectacle lens presented at ARVO 2022 has answered key questions over rebounding effects and the lens’ ability to sustain its myopia controlling effect over time. Read more
Prof Robyn Guymer to head up new 2RT study for iAMD
Adelaide-based Nova Eye Medical says it has navigated a time-consuming and complex series of conversations with the US Food and Drug Administration (FDA) to pave a clear approval pathway for its pioneering 2RT laser system for selected intermediate age-related macular degeneration (iAMD) patients. Read more
Smart glasses from EssilorLuxottica and Meta win prestigious design competitions
Ray-Ban Stories, the smart glasses from EssilorLuxottica and Facebook’s parent company Meta, has claimed awards from two renowned design competitions: the iF Design and Red Dot Design awards. Read more
People on the move – May 2022
Welcome to People on the move – May 2022, Insight’s monthly bulletin to keep the Australian ophthalmic sector updated on new appointments and personnel changes. Read more
SightGlass Vision specs’ two-year data demonstrates myopia control efficacy
Spectacles that use SightGlass Vision’s trademarked Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children, based on 24-month interim data from its pivotal multisite clinical study. Read more
2022 Glaucoma Australia ‘Quinlivan’ research grants open
Researchers in glaucoma have until 31 May 2022 to apply for Glaucoma Australia’s annual ‘Quinlivan’ Research Grants, with the successful recipient/s to be announced on World Sight Day, Thursday 13 October 2022. Read more
Bausch + Lomb eyes AU$1.2 billion in IPO
Ophthalmic giant Bausch + Lomb (B+L), which is being spun-off from its parent as a pure-play eye health company, has filed to raise up to US$840 million (AU$1.2 billion) in an initial public offering (IPO). Read more